.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VIVID and VISTA phase 3 trials were among the landmark studies establishing anti-VEGF therapy for center-involving diabetic macular edema. Patients were randomized to aflibercept 2 mg every four weeks, aflibercept every eight weeks after five monthly loading doses, or macular laser. At 100 weeks, both aflibercept regimens produced substantial and sustained visual-acuity gains, while the laser groups gained very little. Benefits extended beyond letter-score improvement, with more patients achieving meaningful vision gains and improvement in diabetic retinopathy severity. The study supports anti-VEGF therapy as a central component of DME management and provides evidence for a less frequent eight-week maintenance strategy after loading in appropriate patients. For HCPs, treatment decisions should still be personalised around baseline vision, OCT anatomy, systemic diabetic control, adherence and treatment burden. The evidence is directly aligned with AIOC's retina track on anti-VEGF regimens for diabetic macular edema.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VIVID and VISTA phase 3 trials were among the landmark studies establishing anti-VEGF therapy for center-involving diabetic macular edema. Patients were randomized to aflibercept 2 mg every four weeks, aflibercept every eight weeks after five monthly loading doses, or macular laser. At 100 weeks, both aflibercept regimens produced substantial and sustained visual-acuity gains, while the laser groups gained very little. Benefits extended beyond letter-score improvement, with more patients achieving meaningful vision gains and improvement in diabetic retinopathy severity. The study supports anti-VEGF therapy as a central component of DME management and provides evidence for a less frequent eight-week maintenance strategy after loading in appropriate patients. For HCPs, treatment decisions should still be personalised around baseline vision, OCT anatomy, systemic diabetic control, adherence and treatment burden. The evidence is directly aligned with AIOC's retina track on anti-VEGF regimens for diabetic macular edema.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
